SARS-CoV-2/COVID-19 Antibody Test (SCAT), a serologic test for detection of antibodies specific to SARS-CoV-2, and developed by researchers of Armauer Hansen Research Institute (AHRI) and Oregon Health and Science University (OHSU), has received approval by the EFDA for both research purpose and serosurveillance studies.
This is a huge millstone for AHRI and Ethiopia in general as it meets the local demands for SARS-CoV-2 serologic assay and circumvents the lengthy international procurement process. Most importantly, it is relatively cheaper as compared to the commercially available serologic assays with no inferiority in performance (sensitivity and specificity).